Telix Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade 2024-07-18 07:17
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals 2024-07-11 08:21
Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging 2024-06-03 09:08
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer 2024-05-31 07:19
Telix Submits NDA for New Prostate Cancer Imaging Agent 2024-05-27 07:21
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer 2024-05-21 07:58
Q1 2024 Revenue and Business Update 2024-04-17 15:05
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation 2024-04-16 06:42
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain 2024-03-27 05:59
QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy 2024-03-19 05:19
Appointment of Dr Darren Patti to Group Chief Operating Officer 2024-03-12 05:44
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform 2024-03-05 07:01
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics 2024-02-27 05:55
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline 2024-02-22 17:31
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform 2024-02-08 06:11
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024) 2024-01-22 19:00
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference 2024-01-04 06:20
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer 2023-12-19 05:44
First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent 2023-12-11 19:40
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS 2023-12-07 06:45
1 2 3 4 5 7